Provided by Tiger Trade Technology Pte. Ltd.

Ionis Pharmaceuticals

86.50
+3.023.62%
Post-market: 86.730.2325+0.27%17:43 EST
Volume:2.00M
Turnover:171.29M
Market Cap:14.01B
PE:-53.62
High:86.59
Open:84.85
Low:84.18
Close:83.48
52wk High:86.74
52wk Low:23.95
Shares:161.97M
Float Shares:161.00M
Volume Ratio:0.87
T/O Rate:1.24%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6132
EPS(LYR):-3.0358
ROE:-40.04%
ROA:-5.68%
PB:22.67
PE(LYR):-28.49

Loading ...

Ionis Pharmaceuticals Is Maintained at Overweight by Piper Sandler

Dow Jones
·
17 hours ago

Ionis Pharmaceuticals price target raised to $87 from $77 at Piper Sandler

TIPRANKS
·
Yesterday

Ionis Pharmaceuticals EVP and Chief Scientific Officer Frank Bennett Reports Disposal of Common Shares

Reuters
·
Feb 03

Ionis Pharmaceuticals EVP Chief Business Officer Joseph Baroldi Reports Sale of Common Shares

Reuters
·
Feb 03

Has Ionis Pharmaceuticals (IONS) Run Too Far After Its 152% One Year Surge?

Simply Wall St.
·
Jan 30

Ionis Pharmaceuticals assumed with an Overweight at Barclays

TIPRANKS
·
Jan 28

Why Ionis Pharmaceuticals (IONS) Is Up 5.2% After EU Approval of DAWNZERA for HAE Prevention

Simply Wall St.
·
Jan 24

Ionis Pharmaceuticals EVP Shannon L. Devers Reports Sale of Common Shares

Reuters
·
Jan 24

Ionis Pharmaceuticals announces European Commission approval for Dawnzera

TIPRANKS
·
Jan 21

BRIEF-Dawnzera™ (Donidalorsen) Approved In The European Union For Hereditary Angioedema (Hae)

Reuters
·
Jan 21

EU Approves Ionis Pharmaceuticals' DAWNZERA for Hereditary Angioedema Prevention

Reuters
·
Jan 21

Dawnzera™ (Donidalorsen) Approved in the European Union for Hereditary Angioedema (Hae)

THOMSON REUTERS
·
Jan 21

Ionis Pharmaceuticals Inc - Eligible for Milestone Payment of $15 Mln and Tiered Royalties of up to 30% on Net Product Sales

THOMSON REUTERS
·
Jan 21

Ionis Pharmaceuticals EVP and Chief Scientific Officer Frank Bennett Reports Sale of Common Shares

Reuters
·
Jan 21

Analysts Have Conflicting Sentiments on These Healthcare Companies: Hims & Hers Health (HIMS) and Ionis Pharmaceuticals (IONS)

TIPRANKS
·
Jan 19

Analysts Are Bullish on Top Healthcare Stocks: Healthequity (HQY), Ionis Pharmaceuticals (IONS)

TIPRANKS
·
Jan 19

Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD), Ionis Pharmaceuticals (IONS) and DENTSPLY SIRONA (XRAY)

TIPRANKS
·
Jan 16

RBC Capital Keeps Their Buy Rating on Ionis Pharmaceuticals (IONS)

TIPRANKS
·
Jan 14

Ionis Pharmaceuticals (IONS) Gets a Hold from Bernstein

TIPRANKS
·
Jan 14

BRIEF-Biogen Says Co Received European Commission Approval For High Dose Regimen Of SPINRAZA

Reuters
·
Jan 13